Loading stock data…
Summit Therapeutics Inc. (SMMT)
$14.32+0.31 (+2.21%)
Market ClosedLast close Jun 29
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Summit Therapeutics Inc. in the Healthcare sector is trading at $14.32 with a market capitalization of $12.9B. Wall Street consensus targets $28.34 (13 analysts), implying a +97.9% move over the next 12 months. The stock is currently near its 52-week low of $12.55, remaining 19.3% below its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +97.9% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$195.21M↑ | -$224.88M↑ | -$234.21M↑ | -$568.44M↓ | -$66.85M |
| Net Income | -$189.42M↑ | -$219.17M↑ | -$231.79M↑ | -$565.71M↓ | -$62.91M |
Peer Comparison
JNJUNHPFE
Fundamentals
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific a...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$12.90B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-1.25
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-220.92%
Volume
Today's trading volume
5.97M
Recent News
Summit Therapeutics finance chief tops list of public CFO pay in 2025
Manmeet Soni, finance chief of the oncology company, had total compensation of nearly $250 million last year, the highest among CFOs at publicly traded firms in America.
Summit Therapeutics (SMMT): A $500 Million Stock Offering Pulled Just One Day After Filing
Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the most promising healthcare stocks according to Wall Street analysts. On June 10, Summit Therapeutics Inc. (NASDAQ:SMMT) withdrew a $500 million proposed underwritten public offering it had announced just one day earlier. The company cited unfavorable market conditions. The plan was to use the proceeds to fund ongoing […]
Summit Therapeutics (SMMT) Raises $500 Million Through Public Offering
Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the 12 best buy-the-dip stocks to invest in now. On June 10, an underwritten public offering of common stock valued at $500 million was initiated by Summit Therapeutics Inc. (NASDAQ:SMMT). The company stated in its announcement that 100% of the shares in this proposed transaction are being offered […]
Summit Therapeutics Halts US$500m Offering After Ivonescimab Trial Results
Summit Therapeutics (NasdaqGM:SMMT) withdrew its proposed US$500 million public equity offering, citing unfavorable market conditions. The decision came shortly after the company reported positive Phase II/III results for ivonescimab in metastatic colorectal cancer and non small cell lung cancer. The halted funding round pauses an anticipated capital raise that many investors were watching following the ivonescimab data update. Summit Therapeutics focuses on developing ivonescimab as a...
Stocks Settle Sharply Lower on Escalating Middle East Tensions
The S&P 500 Index ($SPX ) (SPY ) on Wednesday closed down -1.62%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down -1.87%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -1.98%. June E-mini S&P futures (ESM26 ) fell -1.62%, and June E-mini Nasdaq futures...